Variability of in situ proteomic profiling and implications for study design in colorectal tumors

Jia Qing Li, Baogang J. Xu, Bashar Shakhtour, Natasha Deane, Nipun Merchant, Martin J. Heslin, Kay Washington, Robert J. Coffey, R. Daniel Beauchamp, Yu Shyr, Dean Billheimer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Knowledge of intrinsic tumor heterogeneity is vital for understanding of tumor progression mechanisms as well as for providing efficient treatments. In situ proteomic profiling of tumors is a powerful technology with potential to enhance our understanding of tumor biology, but sources of variability due to patient and tumor heterogeneity are poorly understood and are the topic of this investigation. Clarification of variability within case and between cases is also important for designing future studies. Direct protein profiling by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a sensitive and powerful technology for obtaining hundreds of protein expression peaks from a thin tissue section. By combining robotic microspotting and laser capture microdissection with MALDI MS, we acquired multiple spectra per case to evaluate inter- and intra-case variability in human colorectal tumor and murine cecal carcinoma. We detected 256 peaks from 164 samples of 111 patients, which consisted of 55 normal colorectal mucosal samples, 24 adenomas, 71 primary carcinomas, and 14 hepatic metastases. In addition, we detected 291 peptide/protein peaks from 34 orthotopically transplanted murine cecal carcinomas and 14 hepatic metastases. In human colorectal samples, we observed that proteomic profiling in adenomas was more homogeneous across patients than in normal mucosa specimens (p=0.0008), but primary carcinoma exhibited greater heterogeneity than normal mucosa and adenomas (both p<0.0001). Murine cecal carcinomas were homogeneous within and between carcinomas, while their hepatic metastases tended toward greater intra-tumor differences (p<0.0001). Inter- and intra-case variability was approximately equal for many protein peaks. Acquiring up to 5 subsamples per case could reduce the total number of cases required, but further reduction from additional subsampling was modest unless intra-case variability comprises a greater proportion of total variation (e.g. >70%). In summary, this study characterizes intra- and inter-case variability of high-throughput protein expression in colorectal tumors, and provides guidance for the sample numbers required for in situ proteomic studies.

Original languageEnglish (US)
Pages (from-to)103-111
Number of pages9
JournalInternational Journal of Oncology
Volume31
Issue number1
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Proteomics
Colorectal Neoplasms
Adenoma
Carcinoma
Neoplasms
Mucous Membrane
Proteins
Neoplasm Metastasis
Laser Capture Microdissection
Technology
Liver
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Robotics
Mass Spectrometry
Lasers
Peptides
Therapeutics

Keywords

  • Colorectal tumor
  • In situ
  • Proteomic profiling
  • Variability

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Li, J. Q., Xu, B. J., Shakhtour, B., Deane, N., Merchant, N., Heslin, M. J., ... Billheimer, D. (2007). Variability of in situ proteomic profiling and implications for study design in colorectal tumors. International Journal of Oncology, 31(1), 103-111.

Variability of in situ proteomic profiling and implications for study design in colorectal tumors. / Li, Jia Qing; Xu, Baogang J.; Shakhtour, Bashar; Deane, Natasha; Merchant, Nipun; Heslin, Martin J.; Washington, Kay; Coffey, Robert J.; Beauchamp, R. Daniel; Shyr, Yu; Billheimer, Dean.

In: International Journal of Oncology, Vol. 31, No. 1, 07.2007, p. 103-111.

Research output: Contribution to journalArticle

Li, JQ, Xu, BJ, Shakhtour, B, Deane, N, Merchant, N, Heslin, MJ, Washington, K, Coffey, RJ, Beauchamp, RD, Shyr, Y & Billheimer, D 2007, 'Variability of in situ proteomic profiling and implications for study design in colorectal tumors', International Journal of Oncology, vol. 31, no. 1, pp. 103-111.
Li, Jia Qing ; Xu, Baogang J. ; Shakhtour, Bashar ; Deane, Natasha ; Merchant, Nipun ; Heslin, Martin J. ; Washington, Kay ; Coffey, Robert J. ; Beauchamp, R. Daniel ; Shyr, Yu ; Billheimer, Dean. / Variability of in situ proteomic profiling and implications for study design in colorectal tumors. In: International Journal of Oncology. 2007 ; Vol. 31, No. 1. pp. 103-111.
@article{a4c5ebffa545499a93f34b749730d0d9,
title = "Variability of in situ proteomic profiling and implications for study design in colorectal tumors",
abstract = "Knowledge of intrinsic tumor heterogeneity is vital for understanding of tumor progression mechanisms as well as for providing efficient treatments. In situ proteomic profiling of tumors is a powerful technology with potential to enhance our understanding of tumor biology, but sources of variability due to patient and tumor heterogeneity are poorly understood and are the topic of this investigation. Clarification of variability within case and between cases is also important for designing future studies. Direct protein profiling by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a sensitive and powerful technology for obtaining hundreds of protein expression peaks from a thin tissue section. By combining robotic microspotting and laser capture microdissection with MALDI MS, we acquired multiple spectra per case to evaluate inter- and intra-case variability in human colorectal tumor and murine cecal carcinoma. We detected 256 peaks from 164 samples of 111 patients, which consisted of 55 normal colorectal mucosal samples, 24 adenomas, 71 primary carcinomas, and 14 hepatic metastases. In addition, we detected 291 peptide/protein peaks from 34 orthotopically transplanted murine cecal carcinomas and 14 hepatic metastases. In human colorectal samples, we observed that proteomic profiling in adenomas was more homogeneous across patients than in normal mucosa specimens (p=0.0008), but primary carcinoma exhibited greater heterogeneity than normal mucosa and adenomas (both p<0.0001). Murine cecal carcinomas were homogeneous within and between carcinomas, while their hepatic metastases tended toward greater intra-tumor differences (p<0.0001). Inter- and intra-case variability was approximately equal for many protein peaks. Acquiring up to 5 subsamples per case could reduce the total number of cases required, but further reduction from additional subsampling was modest unless intra-case variability comprises a greater proportion of total variation (e.g. >70{\%}). In summary, this study characterizes intra- and inter-case variability of high-throughput protein expression in colorectal tumors, and provides guidance for the sample numbers required for in situ proteomic studies.",
keywords = "Colorectal tumor, In situ, Proteomic profiling, Variability",
author = "Li, {Jia Qing} and Xu, {Baogang J.} and Bashar Shakhtour and Natasha Deane and Nipun Merchant and Heslin, {Martin J.} and Kay Washington and Coffey, {Robert J.} and Beauchamp, {R. Daniel} and Yu Shyr and Dean Billheimer",
year = "2007",
month = "7",
language = "English (US)",
volume = "31",
pages = "103--111",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Variability of in situ proteomic profiling and implications for study design in colorectal tumors

AU - Li, Jia Qing

AU - Xu, Baogang J.

AU - Shakhtour, Bashar

AU - Deane, Natasha

AU - Merchant, Nipun

AU - Heslin, Martin J.

AU - Washington, Kay

AU - Coffey, Robert J.

AU - Beauchamp, R. Daniel

AU - Shyr, Yu

AU - Billheimer, Dean

PY - 2007/7

Y1 - 2007/7

N2 - Knowledge of intrinsic tumor heterogeneity is vital for understanding of tumor progression mechanisms as well as for providing efficient treatments. In situ proteomic profiling of tumors is a powerful technology with potential to enhance our understanding of tumor biology, but sources of variability due to patient and tumor heterogeneity are poorly understood and are the topic of this investigation. Clarification of variability within case and between cases is also important for designing future studies. Direct protein profiling by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a sensitive and powerful technology for obtaining hundreds of protein expression peaks from a thin tissue section. By combining robotic microspotting and laser capture microdissection with MALDI MS, we acquired multiple spectra per case to evaluate inter- and intra-case variability in human colorectal tumor and murine cecal carcinoma. We detected 256 peaks from 164 samples of 111 patients, which consisted of 55 normal colorectal mucosal samples, 24 adenomas, 71 primary carcinomas, and 14 hepatic metastases. In addition, we detected 291 peptide/protein peaks from 34 orthotopically transplanted murine cecal carcinomas and 14 hepatic metastases. In human colorectal samples, we observed that proteomic profiling in adenomas was more homogeneous across patients than in normal mucosa specimens (p=0.0008), but primary carcinoma exhibited greater heterogeneity than normal mucosa and adenomas (both p<0.0001). Murine cecal carcinomas were homogeneous within and between carcinomas, while their hepatic metastases tended toward greater intra-tumor differences (p<0.0001). Inter- and intra-case variability was approximately equal for many protein peaks. Acquiring up to 5 subsamples per case could reduce the total number of cases required, but further reduction from additional subsampling was modest unless intra-case variability comprises a greater proportion of total variation (e.g. >70%). In summary, this study characterizes intra- and inter-case variability of high-throughput protein expression in colorectal tumors, and provides guidance for the sample numbers required for in situ proteomic studies.

AB - Knowledge of intrinsic tumor heterogeneity is vital for understanding of tumor progression mechanisms as well as for providing efficient treatments. In situ proteomic profiling of tumors is a powerful technology with potential to enhance our understanding of tumor biology, but sources of variability due to patient and tumor heterogeneity are poorly understood and are the topic of this investigation. Clarification of variability within case and between cases is also important for designing future studies. Direct protein profiling by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a sensitive and powerful technology for obtaining hundreds of protein expression peaks from a thin tissue section. By combining robotic microspotting and laser capture microdissection with MALDI MS, we acquired multiple spectra per case to evaluate inter- and intra-case variability in human colorectal tumor and murine cecal carcinoma. We detected 256 peaks from 164 samples of 111 patients, which consisted of 55 normal colorectal mucosal samples, 24 adenomas, 71 primary carcinomas, and 14 hepatic metastases. In addition, we detected 291 peptide/protein peaks from 34 orthotopically transplanted murine cecal carcinomas and 14 hepatic metastases. In human colorectal samples, we observed that proteomic profiling in adenomas was more homogeneous across patients than in normal mucosa specimens (p=0.0008), but primary carcinoma exhibited greater heterogeneity than normal mucosa and adenomas (both p<0.0001). Murine cecal carcinomas were homogeneous within and between carcinomas, while their hepatic metastases tended toward greater intra-tumor differences (p<0.0001). Inter- and intra-case variability was approximately equal for many protein peaks. Acquiring up to 5 subsamples per case could reduce the total number of cases required, but further reduction from additional subsampling was modest unless intra-case variability comprises a greater proportion of total variation (e.g. >70%). In summary, this study characterizes intra- and inter-case variability of high-throughput protein expression in colorectal tumors, and provides guidance for the sample numbers required for in situ proteomic studies.

KW - Colorectal tumor

KW - In situ

KW - Proteomic profiling

KW - Variability

UR - http://www.scopus.com/inward/record.url?scp=34548593236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548593236&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 103

EP - 111

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -